WNT5A and neoplasm: 6C). The tumor sizes of xenografts of Wnt5A-knockdown MES-SA/Dx5 cells were 2-, 3- and 4-fold reduced in the mean relative tumor volume compared to those of the vector control cells at 7, 14 and 21 days of doxorubicin treatment, respectively (Figure. 6D). Furthermore, xenografts of Wnt5A-knockdown MES-SA/Dx5 cells showed reduced expression levels of ABCB1 and VEGF (Figure. 6E).